AI Article Synopsis
- SGLT-2 inhibitors (SGLT-2i) are linked to weight loss, but it's unclear what type of weight is lost.
- A study analyzed over 3,200 adverse event reports related to musculoskeletal and connective tissue disorders associated with SGLT-2i, revealing specific risks for different drugs like Canagliflozin and Dapagliflozin.
- Findings indicate that AEs can arise shortly after starting SGLT-2i treatment and can persist over time, with notable risks like muscle necrosis and sarcopenia identified.
Article Abstract
Background: The sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) is associated with body weight loss but the composition of the losing weight remains unclear.
Research Design And Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of SGLT-2i-associated musculoskeletal and connective tissue disorders AEs.
Results: The search retrieved a total of 3,206 cases of musculoskeletal and connective tissue disorder-related AEs during the reporting period. This included 1,061 cases for Canagliflozin, 1,052 cases for Dapagliflozin, 1,074 cases for Empagliflozin, and 19 cases for Ertugliflozin. Fifteen preferred terms (PTs) with significant disproportionality were retained. No musculoskeletal and connective tissue system-related AE signals were reported for Ertugliflozin. We identified a risk of muscle necrosis with Canagliflozin use, a risk of sarcopenia with Dapagliflozin use, and a chance of muscle atrophy with Dapagliflozin and Empagliflozin prescriptions. Most cases occurred within the first month after SGLT-2i initiation, and AEs can persist beyond 360 days of use.
Conclusions: Our study identified potential new musculoskeletal and connective tissue disorder-related AE signals associated with SGLT-2 inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2024.2412234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myofascial System and Physical Exercise: A Narrative Review on Stretching (Part I).
Cureus
December 2024
Rehabilitation Medicine, Spine Center, Bologna, ITA.
Over the past 20-30 years, numerous studies have expanded our understanding of the connective components within the human musculoskeletal system. The term "fascia" and, more specifically, the "fascial system" encompass a variety of connective tissues that perform multiple functions. Given the extensive scope of the topic of fascia and the fascial system, which cannot be fully addressed in a single article, this work will focus specifically on the role of fascia in tension transmission (mechanotransduction).
View Article and Find Full Text PDFYoung Doctors Program-Colorado: An Elective Elementary School Program to Improve Health Literacy, Utilization of the Healthcare System, and Osteopathic Awareness.
Med Sci Educ
December 2024
Rocky Vista University College of Osteopathic Medicine, 8401 S. Chambers Rd., Englewood, CO 80112 USA.
The Young Doctors Program (YDP) is a "mini medical school" series for fifth-grade elementary children. The YDP was designed and led by medical students in the Academic Medicine and Leadership Track at the Rocky Vista University College of Osteopathic Medicine in Colorado. The curriculum of the program was designed around the State of Colorado Learning Standards with the purpose of educating students about emergencies and common ailments in five body systems (cardiovascular, respiratory, gastrointestinal, musculoskeletal, and renal) while also providing exposure to healthcare as a profession.
View Article and Find Full Text PDFExploration and evaluation of adverse event signals of droxidopa based on the FAERS database.
Expert Opin Drug Saf
January 2025
Department of Respiratory Medicine, Children's Hospital of Nanjing Medical University, Nanjing, China.
Background: This study aims to utilize the FDA's Adverse Event Reporting System (FAERS) for data analysis to explore the potential adverse events associated with Droxidopa in real-world settings, thereby providing reference information for clinical practice.
Methods: Adverse event reports where Droxidopa was the primary suspected drug were collected from the FAERS database from the third quarter of 2014 to the fourth quarter of 2023. Multiple signal quantification techniques were employed, including ROR, PRR, BCPNN, and MGPS.
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome in a patient with subacute cutaneous lupus (SCLE).
BMJ Case Rep
January 2025
Rheumatology, University of Michigan Michigan Medicine, Ann Arbor, Michigan, USA
A man in his 60s suffered from refractory, biopsy-proven subacute cutaneous lupus erythematosus that required chronic, moderate dose steroids to manage. His rash was accompanied by arthralgias and negative autoantibody testing. His subacute lupus erythematosus (SCLE) was responsive to tofacitinib, but thrombotic complications limited the use of this medication.
View Article and Find Full Text PDFRare vascular complications in classical Ehlers-Danlos syndromes.
BMJ Case Rep
January 2025
Medical Department, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia.
Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders associated with skin, ligament, blood vessel and organ abnormalities. Skin hyperextensibility, joint hypermobility and widened atrophic scars are characteristic of classical EDS. Vascular complications, though rare in classical EDS, can be life-threatening, and this necessitates one to look for vascular associations in non-vascular, such as classical, forms of EDS due to the heterogeneity of the syndrome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!